{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:43:41Z","timestamp":1782459821572,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.transproceed.2018.08.044","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T17:07:33Z","timestamp":1536340053000},"page":"3723-3731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"50","author":[{"given":"K.H.C.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.S.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Recaldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.K.K.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2018.08.044_bib1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00011-017-1032-8","article-title":"The immunological function of CD52 and its targeting in organ transplantation","volume":"66","author":"Zhao","year":"2017","journal-title":"Inflamm Res"},{"key":"10.1016\/j.transproceed.2018.08.044_bib2","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1097\/TP.0000000000001379","article-title":"Impact of immune-modulatory drugs on Treg","volume":"100","author":"Furukawa","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.044_bib3","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1111\/ajt.13739","article-title":"The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients","volume":"16","author":"Furuya","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.044_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/petr.12844","article-title":"Alemtuzumab (Campath-1H) therapy for refractory rejections in pediatric heart transplant recipients","volume":"21","author":"Das","year":"2017","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.transproceed.2018.08.044_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2125.2007.02914.x","article-title":"Population pharmacokinetics\u2013pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response","volume":"64","author":"Mould","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.transproceed.2018.08.044_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40262-017-0573-x","article-title":"Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation","volume":"57","author":"van der Zwan","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.transproceed.2018.08.044_bib7","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1097\/TP.0000000000001346","article-title":"Graft loss and clad onset is hastened by viral pneumonia after lung transplantation","volume":"100","author":"Allyn","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.044_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"70","author":"Kosmidis","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.transproceed.2018.08.044_bib9","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/thx.38.11.822","article-title":"Infectious complications after heart transplantation","volume":"38","author":"Cooper","year":"1983","journal-title":"Thorax"},{"key":"10.1016\/j.transproceed.2018.08.044_bib10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3904\/kjim.2015.30.4.506","article-title":"Infections after lung transplantation: time of occurrence, sites, and microbiologic etiologies","volume":"30","author":"Yun","year":"2015","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.transproceed.2018.08.044_bib11","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1097\/TP.0000000000000687","article-title":"Evaluation of alemtuzumab versus basiliximab induction: a retrospective cohort study in lung transplant recipients","volume":"99","author":"Whited","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.044_bib12","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.healun.2012.01.410","article-title":"400 Ganciclovir-resistant (GCV-R) CMV is common among lung transplant recipients (LTR) receiving alemtuzumab induction and valganciclovir prophylaxis (VGC px), and treatment with foscarnet (FOS) is both ineffective and toxic","volume":"31","author":"Minces","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2018.08.044_bib13","first-page":"A5168","article-title":"Comparative efficacy and side effects of alemtuzumab versus basiliximab as induction agent in lung transplantation","volume":"189","author":"Kolman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.transproceed.2018.08.044_bib14","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.healun.2012.01.289","article-title":"281 Alemtuzumab (Amab) vs. basiliximab (Bmab) induction: impact on infectious and non-infectious outcomes among lung transplant patients (LT pts)","volume":"31","author":"Nguyen","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2018.08.044_bib15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jtcvs.2004.09.040","article-title":"Early outcomes in human lung transplantation with thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy","volume":"130","author":"McCurry","year":"2005","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.transproceed.2018.08.044_bib16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.healun.2011.01.714","article-title":"Five-year outcomes with alemtuzumab induction after lung transplantation","volume":"30","author":"Shyu","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2018.08.044_bib17","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/ajt.12824","article-title":"Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study","volume":"14","author":"Jaksch","year":"2014","journal-title":"Am J Transplant"},{"issue":"Suppl. 5","key":"10.1016\/j.transproceed.2018.08.044_bib18","article-title":"Graft function and transplant vasculopathy after alemtuzumab induction in cardiac transplantation: five year outcomes","volume":"13","author":"Teuteberg","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.044_bib19","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.healun.2009.11.143","article-title":"134: A randomized study using humanized monoclonal antibody against Cd52 (Campath-1h) and tacrolimus in heart transplant recipients","volume":"29","author":"Pham","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2018.08.044_bib20","unstructured":"European Medicines Agency. MabCampath: EPAR - Summary for the public. Vol 20172012."},{"key":"10.1016\/j.transproceed.2018.08.044_bib21","series-title":"Alemtuzumab (Campath) [package insert]","year":"2007"},{"key":"10.1016\/j.transproceed.2018.08.044_bib22","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/TP.0b013e318257ad41","article-title":"Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis","volume":"93","author":"Morgan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2018.08.044_bib23","first-page":"CD008927","article-title":"Antibody induction therapy for lung transplant recipients","volume":"11","author":"Penninga","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transproceed.2018.08.044_bib24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/MOT.0b013e328358000c","article-title":"Current strategies and future trends in immunosuppression after heart transplantation","volume":"17","author":"Aliabadi","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.transproceed.2018.08.044_bib25","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.7182\/pit2012241","article-title":"Alemtuzumab for cytolytic induction of immunosuppression in heart transplant recipients","volume":"22","author":"Cahoon","year":"2012","journal-title":"Prog Transplant"},{"key":"10.1016\/j.transproceed.2018.08.044_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-6143.2007.02053.x","article-title":"Alemtuzumab (Campath-1H) in kidney transplantation","volume":"8","author":"Ciancio","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2018.08.044_bib27","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1086\/510388","article-title":"Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2018.08.044_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","article-title":"Cytomegalovirus infection in transplant recipients","volume":"70","author":"Azevedo","year":"2015","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.transproceed.2018.08.044_bib29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518311874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134518311874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T02:07:36Z","timestamp":1717207656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134518311874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0041134518311874"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.08.044","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2018.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}